Friday, 16 October 2026European Markets

VOLTALIA Stock Went Down By Over 13% At Session Start Today

Loading stream...

(vianews) - shares of voltalia (cac 40: vltsa.pa) slid by a staggering 13.03% to €13.48 at 10:09 est on thursday, after three successive sessions in a row of losses. cac 40 is falling 0.2% to €7,116.57, after three sequential sessions in a row of gains. this seems, so far, a somewhat down trend trading session today.

about voltalia

voltalia sa engages in the production of electricity from renewable energy sources. it operates through two segments, energy sales and services. the company develops, constructs, operates, and maintains wind, solar, hydro, and biomass power plants. it also develops and sells projects, and procures equipment for solar power plants, as well as provides maintenance service. as of december 31, 2021, the company operated solar power plant with an installed capacity of 98 mw. it operates in africa, the middle east, asia, other europe, brazil, and latin america. the company was incorporated in 2005 and is headquartered in paris, france. voltalia sa is a subsidiary of voltalia investissement sa.

earnings per share

as for profitability, voltalia has a trailing twelve months eps of €0.08.

pe ratio

voltalia has a trailing twelve months price to earnings ratio of 162.41. meaning, the purchaser of the share is investing €162.41 for every euro of annual earnings.

volatility

voltalia's last week, last month's, and last quarter's current intraday variation average was a negative 2.87%, a negative 0.65%, and a positive 1.38%.

voltalia's highest amplitude of average volatility was 2.87% (last week), 1.64% (last month), and 1.38% (last quarter).

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, voltalia's stock is considered to be overbought (>=80).

volume

today's last reported volume for voltalia is 138197 which is 204.86% above its average volume of 45330.

more news about voltalia (vltsa.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com